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efining the Approach to Renal
rtery Revascularization
obert D. Safian, MD, FACC, Ryan D. Madder, MD
oyal Oak, Michigan
enal artery stenosis (RAS) is caused by a heterogenous group of diseases with different pathophysiol-
gy, clinical manifestations, treatment approaches, and outcomes. The 2 most common forms of RAS
re ﬁbromuscular dysplasia (FMD) and atherosclerosis (ARAS). Renovascular syndromes are broadly
lassiﬁed into renovascular hypertension and ischemic nephropathy, but these terms are misleading,
ecause they imply a causal relationship between RAS, hypertension, and renal dysfunction, which is
ifﬁcult to prove in humans. Data supporting renal revascularization are limited by heterogeneous
auses of hypertension and renal dysfunction, insufﬁcient understanding of the relationship between
AS and nephropathy, inconsistent techniques for revascularization, ambiguous terminology and end
oints to assess beneﬁt, and lack of large-scale randomized trials. The purpose of this review is to en-
ance understanding of the epidemiology, clinical markers, and diagnosis of RAS; the relationship be-
ween RAS and important disease states; the distinction between renal ischemia and nephropathy; op-
imal revascularization techniques; and avoidance of renal injury. (J Am Coll Cardiol Intv 2009;2:
61–74) © 2009 by the American College of Cardiology Foundationf
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benal artery stenosis (RAS) is caused by a heter-
genous group of diseases with different patho-
hysiology, clinical manifestations, treatment ap-
roaches, and outcomes. The 2 most common
orms of RAS are fibromuscular dysplasia (FMD)
nd atherosclerosis (ARAS), whereas inflamma-
ory disease of the arterial circulation and congen-
tal abnormalities are far less common (Fig. 1).
raditionally, renovascular syndromes have been
roadly classified into 2 categories: renovascular
ypertension and ischemic nephropathy. These
ategories are potentially misleading, because they
mply a causal relationship between RAS and
ypertension or renal dysfunction, respectively.
lthough causal relationships are evident in exper-
mental models of RAS, they are more difficult to
rove in human diseases. Furthermore, a causal
elationship suggests that revascularization of RAS
hould favorably impact blood pressure and renal
rom the Department of Cardiovascular Medicine, William Beaumont
ospital, Royal Oak, Michigan.i
anuscript received July 18, 2008; revised manuscript received Septem-
er 29, 2008, accepted October 10, 2008.unction, yet available clinical data have failed to
emonstrate unequivocal benefits of renal revascu-
arization. The purpose of this review is to place
AS in appropriate perspective, particularly with
egard to renal revascularization and the impor-
ance of renal ischemia and nephropathy. This
See page 183
erspective should incorporate understanding of
he epidemiology, clinical markers, and diagnosis
f RAS; establish a relationship between RAS and
mportant disease states; distinguish renal ischemia
nd nephropathy; use optimal revascularization
echniques; and avoid renal injury.
pidemiology of RAS
MD. Fibromuscular dysplasia is an uncommon dis-
ase of unknown etiology; typically occurs in women
30 years of age; and often affects the renal, carotid,
nd femoral arteries. Fibromuscular dysplasia should
e considered in young patients if severe hypertension
s not associated with obesity, oral contraceptives, or
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162nown renal parenchymal disease. Unilateral or bilateral renal
MD might cause renovascular hypertension, but renal failure
s unusual (1).
RAS. Atherosclerotic renal artery stenosis is a common
linical entity, affecting 7% of patients older than age 65
ears and 60% of patients with hypertension, coronary or
eripheral artery disease, and renal insufficiency (2). Unlike
MD, ARAS rarely causes renovascular hypertension but is
ommonly associated with renal dysfunction (3).
linical Manifestations of RAS
ypertension and cardiovascular manifestations. Hyperten-
ion manifestations include onset of severe hypertension at
ge 30 years (FMD) or at age 55 years (ARAS) and
resistant, accelerated, or malig-
nant hypertension (3). Cardio-
vascular manifestations usually
occur in the setting of malignant
hypertension. The classic mani-
festation is “flash” pulmonary
edema not explained by coronary
artery or valvular disease, espe-
cially if left ventricular function
is normal (4). Other cardiovas-
cular manifestations include se-
vere hypertension associated
with acute coronary syndromes,
acute aortic syndromes, stroke,
transient cerebral ischemia, in-
tracranial hemorrhage, encepha-
lopathy, and papilledema.
Renal manifestations. Renal isch-
emia might present as acute renal
failure, with a rise in serum creat-
inine within 14 days of initiation
of angiotensin-converting enzyme
inhibitors or angiotensin receptor
blockers. Although considered a
arker for bilateral RAS, this observation is neither sensitive
or specific for RAS (5). Other renal manifestations are subtle
r insidious, including unexplained chronic renal failure, small
idney, and asymmetry in renal dimensions (2). Ischemic
ephropathy is an important cause of chronic kidney disease
nd end-stage renal disease, representing the primary etiology
f end-stage renal disease in 5% to 15% of patients initiating
ialysis each year (6).
ssessment of RAS and Its Clinical Significance
creening for RAS. There are no guidelines for routine
creening for RAS. In some patients, the diagnosis of RAS
s made incidentally during angiographic evaluation of lower
bbreviations
nd Acronyms
CC  American College
f Cardiology
HA  American Heart
ssociation
RAS  atherosclerotic
enal artery stenosis
TA  computerized
omography angiography
MD  fibromuscular
ysplasia
FR  glomerular filtration
ate
RA  magnetic resonance
ngiography
AS  renal artery stenosis
RI  renal resistive index
LG  translesional pressure
radient
9MTc-DTPA  technetium-
abeled pentetic acidxtremity arterial diseases, whereas in others a high index of duspicion is required, on the basis of existing guidelines
Table 1). The mere presence of angina, congestive heart
ailure, coronary artery disease, and peripheral artery disease
re not strong indications for evaluation of RAS in the
bsence of other considerations mentioned in the preceding
ext. Impromptu “drive-by” renal arteriography during un-
elated angiographic procedures is not recommended.
stablish the diagnosis of RAS. If clinical manifestations
uggest RAS, the contemporary approach is to use renal
uplex ultrasound, magnetic resonance angiography
MRA), or computerized tomography angiography (CTA)
o identify RAS. Assessment of the renin-angiotensin sys-
em is not recommended (2). Invasive angiography is
ometimes recommended to confirm the diagnosis of RAS;
etermine the etiology; identify dual, accessory, or aberrant
enal arteries; identify diseases of the abdominal aorta; and
valuate the nephrogram. The angiographic technique is
mportant to minimize renal injury, prevent atheroemboli-
ation, and obtain high-quality images. In most cases,
bdominal aortography with digital subtraction provides
uperb images of the abdominal aorta and renal circulation,
ith a power injector and 10 to 15 cc of contrast (Fig. 2).
ecause 30% of patients have dual, accessory, or aberrant
enal arteries (Fig. 3), selective angiography alone might
reclude complete assessment of the renal arteries. Once
anatomic” RAS is recognized, it is important to establish a
elationship between RAS and vital organ injury. The
omplete evaluation of patients with ARAS and vital organ
njury must include a baseline assessment of nephropathy
nd renal ischemia.
elationship Between RAS and
enal Dysfunction
he renal artery, the kidney, and renal function. In simplistic
erms, the kidney is a filter with inflow (renal arteries),
utflow (renal veins), and a reservoir (renal pelvis, ureters,
nd bladder) (Fig. 4). Apart from diseases of outflow (renal
ein obstruction) and collection (obstructive uropathy), filter
ysfunction might be due to inflow impairment (RAS and
enal ischemia) or filter impairment (nephropathy) or both.
hen RAS and nonvascular etiologies of renal dysfunction
o-exist, it might be difficult to establish RAS as the culprit.
atients with nephropathy might not improve after renal
rtery revascularization, depending on the extent of baseline
ephropathy before revascularization and the degree of renal
njury after revascularization (2,7). The relationship be-
ween renal ischemia and nephropathy is central to under-
tanding published studies and ongoing trials of RAS, and
ailure to do so is the most important source of ambiguity
bout the benefits of renal revascularization.
linical evaluation of nephropathy. The clinical evaluation
or nephropathy includes serum creatinine, urinalysis, renal
uplex ultrasound to assess renal dimensions and renal resistive
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163ndex, and selective renal arteriography in some patients to
ssess cortical blood flow and intrarenal arteriolar patterns
Table 2, Fig. 5). Individually, none of these parameters is an
bsolute predictor of outcome, and over-reliance on any single
est might exclude patients who might benefit from revascu-
arization (8). In any given patient, certain measures might
ndicate greater degrees of nephropathy than others, but
dvanced nephropathy is characterized by proteinuria 1
/day, renal length 10 cm, and resistive index 0.8 (2).
Serum creatinine is the most common measure of renal
unction but is limited for assessing the extent of dysfunc-
ion or for distinguishing nephropathy from renal ischemia.
erum creatinine is insensitive to glomerular filtration rate
GFR) until 50% to 75% of renal mass has been lost (Fig. 6).
Figure 2. Conventional Abdominal Aortogram With Digital Subtraction Ang
The early (left), mid (middle), and late (right) phases of contrast injection are
Figure 1. The Most Common Types of Renal Artery Stenosis
(Left) Fibromuscular dysplasia, characterized by a beaded appearance of the m
ﬁbroplasia). (Right) Atherosclerotic renal artery stenosis, characterized by stenogin (see Fig. 3) as well as associated disease of the abdominal aorta and visceral circtated in another way, a patient who loses 50% of renal mass
as might occur after nephrectomy or with unilateral renal
rtery occlusion) should have a normal creatinine; serum
reatinine 2 mg/dl in a patient with unilateral ARAS is
enerally indicative of significant nephropathy (9).
linical evaluation of renal ischemia. Patients with RAS and
bnormal perfusion by objective measurements should be
onsidered to have renal ischemia. Several noninvasive
ethods have utility for estimating renal blood flow, assess-
ng the hemodynamic significance of RAS, and identifying
enal ischemia (Table 3). Nuclear scintigraphy with
echnetium-labeled pentetic acid (99MTc-DTPA) is reliable
or measuring fractional renal blood flow and, when used in
onjunction with 125I-Iothalamate, allows accurate mea-
hy (Anteroposterior Projection)
n. Aortography is used to identify the conﬁguration of the renal arterial ori-
distal renal artery in which the beads are larger than the vessel (medial
the ostium and proximal renal artery.iograp
showid orulation.
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164Table 1. ACC/AHA Guidelines for Renal Arterial Disease (2)
Level of Evidence Class
1. Clinical indications for evaluation for RAS
Hypertension manifestations
Hypertension onset age 30 yrs (FMD) B I
Hypertension onset age 55 yrs (ARAS) B I
Resistant hypertension C I
Accelerated hypertension C I
Malignant hypertension C I
Renal manifestations
Acute renal failure after ACEI/ARB B I
Unexplained small kidney B I
Asymmetry in renal dimensions 1.5 cm B I
Unexplained chronic renal failure B II A
New dialysis B II A
Cardiovascular manifestations
Unexplained pulmonary edema B I
Multivessel CAD alone B II B
PAD alone B II B
Unexplained CHF C II B
Refractory angina C II B
2. Screening tests for RAS
RDU, MRA, CTA B I
Contrast angiography for ambiguous noninvasive tests B I
Captopril renal scintigraphy C III
Selective renal vein sampling B III
Plasma renin activity B III
Captopril-stimulated renin secretion B III
3. Indications for revascularization*
Asymptomatic bilateral ARAS C II B
Asymptomatic solitary ARAS C II B
Asymptomatic unilateral ARAS C II B
RAS and Class I indications for RAS evaluation B II A
RAS and intolerance to medication B II A
Bilateral ARAS and progressive renal dysfunction B II A
Solitary ARAS and progressive renal dysfunction B II A
Unilateral ARAS and chronic renal dysfunction C II B
ARAS and unexplained pulmonary edema B I
ARAS and unexplained recurrent CHF B I
ARAS and unstable angina B II A
4. Recommendations for pharmacological treatment
ACEI or ARB for RAS and hypertension A I
Calcium channel blockers for RAS and hypertension A I
Beta-blockers for RAS and hypertension A I
5. Type of renal artery revascularization
Renal stent for ARAS patients who meet criteria B I
Angioplasty for FMD, with bailout stenting B I
Class I: conditions for which there is evidence for and/or general agreement that a given procedure or treatment is beneficial, useful, and effective. Class II: conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment. Class IIa: weight of evidence/opinion is in favor of usefulness/efficacy. Class IIb: usefulness/efficacy is less-well-
established by evidence/opinion. Class III: conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases might be harmful. Level of
Evidence A: data derived from multiple randomized clinical trials or meta-analyses. Level of Evidence B: data derived from a single randomized trial or nonrandomized studies. Level of Evidence C: only
consensus opinion of experts, case studies, or standard-of-care. *Assumes hemodynamically significant ARAS.
ACC/AHAAmericanCollegeof Cardiology/AmericanHeartAssociation; ACEI angiotensin convertingenzyme inhibitor; ARAS atherosclerotic renal artery stenosis; ARB angiotensin receptor blocker;
CAD coronary artery disease; CHF congestive heart failure; CTA computerized tomography angiography; FMD fibromuscular dysplasia; MRAmagnetic resonance angiography; PAD peripheralarterial disease; RAS renal artery stenosis; RDU renal duplex ultrasound.
s
p
k
w
i
h
p
e
l
p
c
d
d
f
b
I
v
a
i
l
a
b
i
s
(
ition. P
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 3 , 2 0 0 9
M A R C H 2 0 0 9 : 1 6 1 – 7 4
Safian and Madder
Renal Artery Revascularization
165urement of total- and single kidney-GFR (10–12). In
atients with unilateral RAS, hypoperfusion of the stenotic
idney is reasonable evidence for renal ischemia; patients
ith normal renal blood flow might have RAS but not
schemia.
The invasive evaluation of renal ischemia is based on
emodynamic assessment of RAS rather than renal artery
erfusion per se. Stenosis severity determined by visual
stimates or quantitative angiography has a poor corre-
ation with hemodynamic significance (13). Translesional
ressure gradients (TLG) 20 mm Hg, with small
atheters or special pressure wires, are considered hemo-
ynamically significant (14). Fractional flow reserve can
etermine the hemodynamic significance of RAS, and
Figure 3. Schematic Representation of Common Configurations of Renal A
(A) Single renal artery occurs in 55% of population. (B) Single renal artery with
which 2 major renal arteries supply a single kidney occurs in 8% of population
in 7% of population. Other conﬁgurations (not shown) occur in 16%, including
aortic bifurcation (modiﬁed from Uﬂacker R. Atlas of Vascular Anatomy, 2nd ed
Figure 4. Schematic Representation of the Kidney as a Filter
Overall ﬁlter function is inﬂuenced by inﬂow to the ﬁlter (renal artery ste-
nosis and renal ischemia), integrity of the ﬁlter (nephropathy), outﬂow from
the ﬁlter (renal vein obstruction), and disorders of collection (obstructive
uropathy).ractional flow reserve 0.80 might predict a favorable
lood pressure response to revascularization (13,15).
ntravascular ultrasound is extremely useful for assessing
essel dimensions and stenosis severity in FMD patients
nd, when used with TLG, provides useful assessment of
schemia and improvement after angioplasty. Intravascu-
ar ultrasound might be used to guide stenting for
mbiguous ARAS (16). Renal frame counts and renal
lush scores are used to assess the hemodynamic signif-
cance of RAS (17), but high frame counts and low blush
cores might be observed with nephropathy without RAS
18–20).
Table 2. Clinical Evaluation of Renal Parenchymal Disease (Nephropathy)
Factor Comment
Serum creatinine Easy to measure and inexpensive. Relatively insensitive to
degree of renal dysfunction (see Fig. 6) and not reliable
for differentiating nephropathy from renal ischemia.
Proteinuria Easy to measure and inexpensive. Proteinuria 1 g/24 h is
a good indication of nephropathy, but lesser degrees of
proteinuria are less reliable.
Renal dimensions Renal length 10–12 cm is generally favorable. Renal length
6 cm indicates irreversible renal injury (atrophic
kidney).
RRI RRI 0.7 is a good measure of reversibility. Although RRI
0.8 indicates parenchymal disease, it should not be
used as the sole indicator of irreversible renal
dysfunction.
Renal arteriogram Preservation of cortical blood ﬂow and absence of intra-
renal arteriolar disease are indicators of reversible renal
dysfunction. Poor cortical blood ﬂow and severe diffuse
intrarenal arteriolar disease are markers of advanced
nephropathy (see Fig. 5).
Renal biopsy Reliable for histologic conﬁrmation of nephropathy but
not practical for most patients
Origins From the Abdominal Aorta
bifurcation occurs in 14% of population. (C) Dual arterial circulation in
ingle major renal artery and 1 or more smaller accessory renal arteries occur
ant origins of the renal arteries from other visceral vessels, iliac arteries, and
hiladelphia, Pennsylvania: Lippincott, Williams, and Wilkins, 2007:609).rterial
early
. (D) S
aberrRRI renal resistive index.
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166ew classiﬁcation for RAS, renal ischemia, and nephropa-
hy. We propose the following classification to allow iden-
ification of patients with and without nephropathy and
ith and without renal ischemia (Table 4, Fig. 7): Type 1:
ormal kidneys (no nephropathy); Type 2: nephropathy
parenchymal disease); Type A: no renal ischemia (hemo-
ynamically insignificant RAS); and Type B: renal ischemia
hemodynamically significant RAS).
This classification offers a reasonable framework for
valuation of patients with RAS and allows identification
f patients with normal (Type 1) and abnormal (Type 2)
idneys and with normal (Type A) and abnormal (Type
) renal perfusion. The goals of the classification are to
rovide more consistent terminology, offer a framework
or evaluating renal ischemia and nephropathy, and guide
Figure 5. Arteriographic Patterns of Progressive Nephropathy
(A) Normal kidney (renal resistive index [RRI] 0.6) with normal cortical blood ﬂ
with mild diffuse intrarenal arteriolar narrowing and preserved cortical ﬂood ﬂ
blood ﬂow, vascular pruning (arrows), and diffuse intrarenal arteriolar narrowi
cal blood ﬂow and extensive intrarenal arteriolar disease.anagement decisions. The best candidates for revascu- warization are those with vital organ injury, renal isch-
mia, and no nephropathy.
enal Artery Revascularization:
echnical Considerations
echnique of renal artery revascularization. For FMD pa-
ients, balloon angioplasty is the intervention of choice, and
tenting is used for bail-out indications. Procedural success
pproaches 100%, and restenosis occurs in 10% within 10
ears (21,22). Renal angioplasty is better in discrete lesions
n major renal arteries and worse in diffuse FMD in small
egmental, arcuate, and interlobar vessels. Because renal
rteriography is not reliable for assessment of FMD stenosis
everity or vessel dimensions, we recommend the pressure
d intrarenal arteriolar circulation. (B) Mild hypertensive nephropathy (RRI 0.7)
) Advanced hypertensive nephropathy (RRI 0.8), with diminished cortical
) End-stage kidney due to hypertensive nephropathy (RRI 0.9). with no corti-ow an
ow. (C
ng. (Dire and intravascular ultrasound to assess TLG, vessel
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167imensions, and stenosis severity. Patients with nonobstruc-
ive FMD should be treated conservatively.
In patients with ARAS, stenting is recommended to
liminate elastic recoil, minimize dissection, and maximize
umen enlargement (Fig. 8). Most studies report procedural
uccess rates of 95% to 100%, residual diameter stenosis
10 %, restenosis rates of 10% to 15% within 1 year, and
ajor complications in 2% (14).
There are a number of important technical and proce-
ural considerations to avoid renal artery injury, kidney
njury, and atheroembolization. Selective renal arteriogra-
hy should be guided by abdominal aortography; the
atheter-in-catheter or no-touch techniques should be used
o minimize contact with the aortic wall and injury to the
enal ostium during guiding catheter engagement (23) (Fig.
). The nephrotoxic effects of radiographic contrast are
inimized by maintaining adequate hydration, limiting
ontrast volume, and using digital subtraction angiography.
enal embolization during revascularization seems to be
airly common (24), and 1 small randomized study sug-
ested potential benefit of a combination of distal embolic
rotection and intravenous abciximab (25). Because 14% of
atients have early renal bifurcations, complete renal “pro-
ection” might not be possible. All patients should be
valuated for post-procedural nephropathy and have regular
ollow-up.
utcomes After Renal Artery Revascularization
ailure of renal revascularization to cure hypertension. After
RAS revascularization, hypertension cure (normal blood
ressure, no medication) is observed in 10% of patients,
Figure 6. Relationship Between GFR and Serum Creatinine Concentration
Loss of 50% of glomerular ﬁltration rate (GFR) is not associated with mea-
surable elevation of serum creatinine. When 75% of GFR is lost, there is a
strong relationship between GFR and serum creatinine (modiﬁed from ref-
erence [9]).egardless of the revascularization technique (26,27). Thexplanations for why renal revascularization does not cure
ypertension are somewhat speculative, and available data
re limited by heterogeneous causes of hypertension and
enal dysfunction, insufficient understanding of the relation-
hip between renal ischemia and nephropathy, inconsistent
echniques for revascularization, ambiguous terminology
nd end points to assess clinical benefit, and the lack of
arge-scale randomized trials. There is a persistent misper-
eption that ARAS patients have renovascular hypertension,
nd contemporary reviews continue to use this terminology
14,26). Whereas the experimental Goldblatt models are
ompelling demonstrations of renin-angiotensin activation
ue to RAS (28), the mechanisms of hypertension in
umans with and without RAS are far more complex and
nclude sympathetic and cerebral nervous system activation,
asoactive oxygen species, abnormalities in endothelial de-
endent relaxation, and ischemic and hypertensive intra-
enal injury (29–31). Patients with ARAS do not have
enovascular hypertension, as evidenced by similarities in
he extent of renin activation compared with hypertensive
atients without RAS and the low cure rate of hypertension
fter successful revascularization (32,33). The most likely
xplanations are that patients with ARAS have essential
ypertension, many do not have renal ischemia, and unrec-
gnized hypertensive nephropathy leads to self-perpetuating
ypertension.
ailure of renal revascularization to improve renal function.
everal studies documented improvement in creatinine and
n the slope of reciprocal creatinine after stenting, compat-
ble with beneficial effects of revascularization on renal
unction (34–36). Nevertheless, 25% to 30% have deterio-
ation in renal function despite revascularization. The ex-
lanations for failure to improve or stabilize renal function
fter revascularization are multifactorial, including revascu-
arization of patients without renal ischemia, insensitivity of
he creatinine to changes in GFR when50% of renal mass
s revascularized (e.g., unilateral ARAS) (Fig. 6), failure to
dentify baseline nephropathy, and procedure-induced ne-
hropathy. The key observation in prior studies of ischemic
ephropathy is the crucial importance of baseline renal
Table 3. Clinical Evaluation of Renal Artery Perfusion and Renal Ischemia
Noninvasive assessment of renal blood ﬂow
125I-Iothalamate GFR (Total GFR)
99MTc-DTPA (split renal function and single-kidney GFR)
Invasive assessment of signiﬁcance of RAS
Percent diameter stenosis by visual estimates or quantitative angiography
Translesional pressure gradient
Fractional ﬂow reserve
Intravascular ultrasound
Renal frame counts
Renal blush score
GFR glomerular filtration rate; RAS renal artery stenosis; 99MTc-DTPA technetium-labeledpentetic acid.
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168unction (36–38): Baseline creatinine 1.5 mg/dl is the
ingle strongest predictor of late death (39), and the risk of
enal failure rises 3-fold for each increment of 1.0 mg/dl in
aseline creatinine (3).
RAS and cardiovascular outcomes. Four-year survival rates
re 57% and 89% for patients with and without ARAS,
espectively, and mortality rates are higher with more severe
RAS and with bilateral ARAS (2,40). Although ARAS
dds incremental risk to cardiovascular morbidity and mor-
ality, there are no data that renal revascularization improves
ardiovascular outcomes. The CORAL (Cardiovascular
utcomes in Renal Atherosclerotic Lesions) trial is ran-
omizing 1,080 patients with ARAS to optimal medical
herapy or to optimal medical therapy plus renal artery
tenting (41). Patients must have unilateral or bilateral
RAS, resistant hypertension, and/or chronic kidney dis-
ase stage 3. The primary end point is a composite of
ardiovascular or renal death, stroke, myocardial infarction,
ospital stay for heart failure, progressive renal insufficiency,
r the need for renal replacement therapy. The results of
ORAL are expected in 2010; a potentially important
imitation is the lack of baseline assessment of nephropathy
nd renal ischemia.
pproach to Specific Clinical Situations
ypertensive RAS patients without vital organ injury. In
lder patients with new or refractory hypertension, imaging
tudies are reasonable to detect ARAS, but revascularization
s controversial in the absence of renal ischemia or cardio-
ascular injury (Fig. 10). For patients with no nephropathy
Table 4. Classification of RAS, Renal Perfusion, and Renal Parenchymal Di
Type I A I
Perfusion NL* Renal ische
Parenchymal disease No No
Scr NL URAS–NL
BRAS–NL o
Proteinuria No No
RRI 0.7 0.7
Arteriolar narrowing None None or m
Arteriolar pruning None None
Cortical blood ﬂow NL NL
Biopsy NL NL
Nuclear GFR NL URAS: NL
DTPA split function BRAS: NL o
URAS: SYM URAS: ASY
BRAS: SYM BRAS: SYM
TLG None 20 mm H
FFR NL 0.8
*These patients have “anatomic” renal artery stenosis (RAS) but no renal ischemia (normal perfusio
1 increased;2decreased; ASYM asymmetric; BRASbilateral renal artery stenosis; DTPA
RRI renal resistive index; Scr serum creatinine; SYM symmetric; TLG translesional pressurend normal renal blood flow (Type 1A), we would intensify vhe antihypertensive regimen and follow patients clinically
or the development of vital organ injury. For patients with
nilateral or bilateral ARAS, no nephropathy, and abnormal
erfusion, we would “reclassify” such patients as having
enal ischemia (Type 1B).
ypertensive patients with vital organ injury. Hypertensive
atients with manifestations of vital organ injury should
ndergo an imaging study to detect RAS. The best candi-
ates for revascularization are those with minimal or no
ephropathy and renal ischemia (Type 1B). The worst
andidates are those with advanced nephropathy (Type 2),
specially if renal ischemia is absent (Type 2A).
enal FMD. For asymptomatic patients 30 years old with
ontrolled or resistant hypertension, CTA is reasonable to
iagnose FMD. Recommendations for revascularization are
nfluenced by patient age, FMD location and distribution,
emodynamic significance of stenosis, and tolerance of
ntihypertensive medication. In the majority, angioplasty is
ppropriate to control hypertension. Because 25% of pa-
ients with renal FMD have carotid FMD, carotid duplex
ltrasound is recommended if renal FMD is identified. In
ddition, patients with carotid FMD might have berry
neurysms of the circle of Willis, so intracranial MRA or
TA is advisable, too. Decisions about revascularization of
enal FMD are simpler than ARAS, because of the high
80%) cure rate and durability (90% patency at 10 years)
fter angioplasty. Because hypertensive FMD patients gen-
rally have renovascular hypertension, angiotensin convert-
ng enzyme inhibitors and angiotensin receptor blockers are
sually effective. Patients who do not respond or develop
II A II B
NL* Renal ischemia
Yes Yes
NL or 1 NL or 1
Might be present Might be present
0.8 0.8
Yes Yes
Yes Yes
2 2
Abnormal Abnormal
2 URAS: 2
BRAS: 2
URAS: SYM URAS: ASYM
YM BRAS: SYM BRAS: SYM or ASYM
None 20 mm Hg
NL 0.8
c-labeledpentetic acid; FFR fractional flow reserve; GFRglomerular filtration rate; NLnormal;
t; URAS unilateral renal artery stenosis.sease
B
mia
r 1
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r 2
M
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g
n).
 99M-Tital organ injury should be considered for revascularization.
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169linical follow-up is recommended; uncontrolled hyperten-
ion or new vital organ injury should prompt repeat invasive
valuation.
nilateral ARAS. If studies demonstrate normal kidneys and
enal ischemia (Type 1B), we consider this a manifestation
f “unilateral” vital organ injury. This form of renal ischemia
s not mentioned in American College of Cardiology/
merican Heart Association (ACC/AHA) guidelines, but
uch patients could be considered for renal stenting. The
hysician might be confronted by a more challenging
ecision in patients with serum creatinine 2 mg/dl and
Figure 7. Schematic Illustration of Disorders of Nephropathy (Type 1 or 2)
Type 1A  normal kidneys, no renal ischemia: in the presence of unilateral or
glomerular ﬁltration rate (GFR), and single-kidney GFR (SK-GFR) are normal, an
presence of renal ischemia and unilateral ARAS, Scr and total GFR are normal,
RAS, Scr and total GFR are normal, and SK-GFR is abnormal. Renal blood ﬂow
renal ischemia: in the presence of unilateral or bilateral ARAS, Scr, total GFR, a
thy, renal ischemia: in the presence of unilateral ARAS, Scr, total GFR, and SK-G
GFR, and SK-GFR are abnormal, and renal blood ﬂow might be symmetric (sho
and complements the nuclear blood ﬂow evaluation, particularly when nephronilateral ARAS. In these patients, nephropathy is highly iikely (Type 2), and preservation of renal function is less
ikely after revascularization. If such patients develop car-
iovascular injury, renal revascularization might be reason-
ble if renal ischemia is present (Type 2B), although renal
unction might not improve; recommendations in these
atients should be individualized.
ilateral ARAS or ARAS of a solitary kidney. Patients with
ilateral ARAS or ARAS of a solitary kidney might have
lobal severe renal ischemia and are more prone to pulmo-
ary edema than those with unilateral RAS. Patients with
evere bilateral ARAS, minimal or no nephropathy, renal
enal Ischemia (Type A or B)
ral atherosclerotic renal artery stenosis (ARAS), serum creatinine (Scr), total
l perfusion is symmetric. Type 1B  normal kidneys, renal ischemia: in the
tic kidney GFR is abnormal, and renal blood ﬂow is asymmetric. With bilateral
be symmetric (shown here) or asymmetric. Type 2A  nephropathy, no
-GFR are abnormal and, renal perfusion is symmetric. Type 2 B  nephropa-
e abnormal, and renal perfusion is asymmetric. With bilateral ARAS, Scr, total
re) or asymmetric. Invasive assessment of renal ischemia might be useful
is present.and R
bilate
d rena
steno
might
nd SK
FR ar
wn heschemia (Type 1B), and cardiovascular injury are ideal
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170Figure 8. Endovascular Revascularization of Atherosclerotic Renal Artery Stenosis
(Left) Baseline image before intervention (same as Fig. 1, right panel). (Middle) Suboptimal angiographic result after balloon angioplasty, characterized by signif-
icant residual stenosis, elastic recoil, and dissection (arrow). (Right) Final result after stent placement demonstrates optimal lumen enlargement.Figure 9. Schematic Illustrations of Invasive Techniques to Avoid Renal Artery Injury and Atheroembolization During Renal Artery Stenting
(Left) Catheter-in-catheter technique employs a tapered 4- or 5-F soft-tip diagnostic catheter loaded inside a 6- or 7-F guiding catheter. After the renal artery is
engaged with the diagnostic catheter, the 0.014-inch angioplasty wire is advanced across the stenosis and positioned distally. The guiding catheter is
advanced over the diagnostic catheter, and once positioned the diagnostic catheter is removed. (Right) The no-touch technique uses a 0.035-inch J wire
inside the guiding catheter, to lift the tip off the aortic wall. With the 0.035-inch wire in place, the guiding catheter is aligned with the renal artery, and a
0.014-inch guidewire is used to cross the stenosis. The 0.035-inch guidewire is removed, and the guiding catheter is advanced over the 0.014-inch wire to
engage the renal artery.
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171andidates for renal revascularization. Evidence for ne-
hropathy might be missed if serum creatinine is the only
easure of renal function. Such patients should be consid-
red for revascularization if nuclear GFR is 60 cc/min/
.73 m2, even in the absence of cardiac or cerebral dysfunc-
ion, before the development of more advanced renal
ysfunction. Nuclear blood flow studies and/or invasive
ssessment of ischemia are useful in patients with bilateral
RAS to identify the more hemodynamically impaired
enal artery and to serve as a baseline for follow-up.
atients with end-stage renal disease. In the absence of
iabetes or other confirmed nephropathy, it is reasonable to
erform an imaging study to diagnose ARAS in patients
ho have been on dialysis for 1 year (2). Patients with
nilateral stenosis or occlusion are unlikely to benefit, but
atients with bilateral ARAS or occlusion might separate
rom dialysis after renal revascularization (Fig. 11) (42).
ollow-up of patients with RAS. There are no ACC/AHA
uidelines for following patients with RAS. Our approach
o all RAS patients includes semiannual assessment of blood
ressure, serum creatinine, and vital organ injury. We obtain
nnual or biannual evaluation of nuclear GFR and split
enal blood flow for ARAS patients. After stenting for
RAS, we repeat nuclear blood flow studies at 3 months
nd annually thereafter. Initial improvement in stented-
idney GFR followed by deterioration is suggestive of
Figure 10. Algorithm for the Evaluation, Treatment, and Follow-Up of Patie
RAS  renal artery stenosis.estenosis. oonclusions
espite publication of the 2005 ACC/AHA guidelines,
here is persistent controversy about renal artery revascular-
zation. This controversy stems from imprecise understand-
ng of renal vascular syndromes and their relationship to
ypertension and renal dysfunction and is compounded by
ailures to differentiate renal ischemia from nephropathy,
esulting in confusing and conflicting data about outcomes.
ccordingly, we propose “new rules” for patients with renal
ascular diseases (Table 5):
ule #1: The term “renovascular hypertension” should be
eserved specifically for patients with renin-dependent hy-
ertension, in whom revascularization is expected to cure
ypertension. For practical purposes, this is true for many
atients with FMD but not with ARAS.
ule #2: Hypertension in patients with ARAS might be
lassified as controlled, refractory, accelerated, or malignant,
epending on the clinical circumstances. Patients with
RAS and hypertension should not be classified as having
renovascular hypertension,” because there is no compelling
vidence that ARAS causes hypertension, and cure of
ypertension after revascularization is rare.
ule #3: The term “renal ischemia” should be reserved for
atients with RAS and abnormal renal perfusion (unilateral
ith RASnts Wr bilateral).
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172ule #4: The term “renal artery stenosis” should be used for
atients with “anatomic” stenosis but has no implications
egarding renal ischemia.
Figure 11. Renal Arteriographic Findings in a 72-Year-Old Man With End-St
Left and right panels demonstrate chronic total occlusion of the right and le
balloon angioplasty (middle, arrows), and widely patent renal arteries after st
stable serum creatinine of 1.5 to 1.7 mg/dl but died after a large stroke due to
Table 5. New Terminology for Renal Vascular Diseases
Hypertension
Renovascular hypertension: renin-dependent hypertension, typical of young patien
revascularization.
Essential hypertension: typical form of hypertension in elderly persons, associated
hypertension is absent.
Controlled hypertension: blood pressure controlled with 2 medications accord
Refractory hypertension: blood pressure exceeds current guidelines despite 3
Accelerated hypertension: previously controlled hypertension becomes progress
multiple additional medications.
Malignant hypertension: uncontrolled hypertension associated with acute renal
Renal artery stenosis (no ischemia)
Unilateral RAS: anatomic unilateral RAS without objective renal ischemia
Bilateral RAS: anatomic bilateral RAS without objective renal ischemia
Renal ischemia
Unilateral RAS: objective renal ischemia in the distribution of the stenotic renal ar
Bilateral RAS: objective renal ischemia in one or both renal arteries.
Nephropathy (parenchymal disease)
Ischemic nephropathy: renal parenchymal disease due to long-standing intrarenal
Diabetic nephropathy: renal parenchymal disease due to long-standing diabetes.
Hypertensive nephropathy: renal parenchymal disease due to long-standing hyper
Other nephropathies: renal parenchymal diseases associated with other known glo
Procedure related nephropathy: acquired parenchymal injury (transient or perman
embolization, or other causes.Abbreviations as in Table 1.ule #5: The term “nephropathy” should be reserved for
atients with renal parenchymal disease. “Ischemic ne-
hropathy” should be reserved for patients with renal
enal Failure on Dialysis for 7 Months
l arteries, respectively (top), high-grade residual stenosis and dissection after
(bottom). He remained off dialysis for 7 years after revascularization with a
iac embolization from atrial ﬁbrillation.
h FMD; characterized by high likelihood of cure of hypertension after
anifestations of atherosclerosis; causal relationship between ARAS and
current guidelines.
tions.
ncontrolled, exceeds current guidelines, and remains poorly controlled despite
iovascular injury.
lar disease associated with generalized atherosclerosis.
n, intrarenal arteriolar disease, and self-perpetuating hypertension
ar or interstitial renal diseases.
at might be related to acute tubular necrosis, radiographic contrast, renalage R
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173arenchymal disease associated with longstanding athero-
clerosis and intrarenal arteriolar disease. Other forms of
ephropathy might be based on the presence of known
iseases, such as diabetes (diabetic nephropathy), hyperten-
ion (hypertensive nephropathy), or interstitial diseases
interstitial nephropathy) or might be acquired as a compli-
ation of revascularization (acute tubular necrosis, contrast
ephropathy, and renal embolization).
ule #6: Medical therapies, particularly antihypertensive
rug therapy and therapies to limit ARAS, are the primary
herapies for all patients with RAS.
ule #7: The optimal use of renal artery revascularization is
oorly defined. Contemporary decisions about renal revas-
ularization must include an assessment of the severity and
unctional significance of RAS (renal ischemia), the condi-
ion of the kidneys (nephropathy), and the association
etween RAS and vital organ injury.
ule #8: The benefits and risks of renal revascularization
ill be improved by careful patient selection. Better results
ill be achieved in patients with vital organ injury, renal
schemia, and no nephropathy.
ule #9: Appropriately designed randomized clinical trials
re essential to define the role of renal revascularization.
uch trials must incorporate assessment of renal ischemia
nd nephropathy, because these factors have the strongest
nfluence on outcome.
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